146798-66-5,MFCD00938565
Catalog No.:AA001E9H

146798-66-5 | Piperidine, 3-[3-(methylsulfonyl)phenyl]-1-propyl-, (3S)-

Pack Size
Purity
Availability
Price(USD)
Quantity
  
1mg
95%
1 week  
$280.00   $196.00
- +
5mg
95%
1 week  
$557.00   $390.00
- +
10mg
95%
1 week  
$796.00   $557.00
- +
25mg
95%
1 week  
$1,186.00   $830.00
- +
50mg
95%
1 week  
$1,635.00   $1,144.00
- +
100mg
95%
1 week  
$2,183.00   $1,528.00
- +
500mg
95%
1 week  
$4,309.00   $3,016.00
- +
  • Technical Information
  • Properties
  • Literature
  • Request for Quotation
  • Download SDS
Technical Information
Catalog Number:
AA001E9H
Chemical Name:
Piperidine, 3-[3-(methylsulfonyl)phenyl]-1-propyl-, (3S)-
CAS Number:
146798-66-5
Molecular Formula:
C15H23NO2S
Molecular Weight:
281.4136
MDL Number:
MFCD00938565
SMILES:
CCCN1CCC[C@H](C1)c1cccc(c1)S(=O)(=O)C
Properties
Properties
 
Storage:
2-8℃;Inert atmosphere;  

Computed Properties
 
Complexity:
374  
Covalently-Bonded Unit Count:
1  
Defined Atom Stereocenter Count:
1  
Defined Bond Stereocenter Count:
0  
Formal Charge:
0  
Heavy Atom Count:
19  
Hydrogen Bond Acceptor Count:
3  
Hydrogen Bond Donor Count:
0  
Isotope Atom Count:
0  
Rotatable Bond Count:
4  
Undefined Atom Stereocenter Count:
0  
Undefined Bond Stereocenter Count:
0  
XLogP3:
2.6  

Literature

Title: Synthesis and evaluation of a set of 4-phenylpiperidines and 4-phenylpiperazines as D2 receptor ligands and the discovery of the dopaminergic stabilizer 4-[3-(methylsulfonyl)phenyl]-1-propylpiperidine (huntexil, pridopidine, ACR16).

Journal: Journal of medicinal chemistry 20100325

Title: Coadministration of (-)-OSU6162 with l-DOPA normalizes preproenkephalin mRNA expression in the sensorimotor striatum of primates with unilateral 6-OHDA lesions.

Journal: Experimental neurology 20010501

Title: Effects of acute and repeated treatment with a novel dopamine D2 receptor ligand on L-DOPA-induced dyskinesias in MPTP monkeys.

Journal: European journal of pharmacology 20010202

Title: (-)-OSU 6162 inhibits levodopa-induced dyskinesias in a monkey model of Parkinson's disease.

Journal: Neuroreport 19970728

Quotation Request
Company Name:
*
Contact Person:
*
Email:
*
Quantity Required:
*
Country:
Additional Info:
SDS
Historical Records
Tags:146798-66-5 Molecular Formula|146798-66-5 MDL|146798-66-5 SMILES|146798-66-5 Piperidine, 3-[3-(methylsulfonyl)phenyl]-1-propyl-, (3S)-
Catalog No.: AA001E9H
146798-66-5,MFCD00938565
146798-66-5 | Piperidine, 3-[3-(methylsulfonyl)phenyl]-1-propyl-, (3S)-
Pack Size: 1mg
Purity: 95%
1 week
$280.00 $196.00
Pack Size: 5mg
Purity: 95%
1 week
$557.00 $390.00
Pack Size: 10mg
Purity: 95%
1 week
$796.00 $557.00
Pack Size: 25mg
Purity: 95%
1 week
$1,186.00 $830.00
Pack Size: 50mg
Purity: 95%
1 week
$1,635.00 $1,144.00
Pack Size: 100mg
Purity: 95%
1 week
$2,183.00 $1,528.00
Pack Size: 500mg
Purity: 95%
1 week
$4,309.00 $3,016.00
Quantity
- +
Add to Card
Order Now
bulk Quotation Request
Technical Information
Catalog Number: AA001E9H
Chemical Name: Piperidine, 3-[3-(methylsulfonyl)phenyl]-1-propyl-, (3S)-
CAS Number: 146798-66-5
Molecular Formula: C15H23NO2S
Molecular Weight: 281.4136
MDL Number: MFCD00938565
SMILES: CCCN1CCC[C@H](C1)c1cccc(c1)S(=O)(=O)C
Properties
Storage: 2-8℃;Inert atmosphere;  
Complexity: 374  
Covalently-Bonded Unit Count: 1  
Defined Atom Stereocenter Count: 1  
Defined Bond Stereocenter Count: 0  
Formal Charge: 0  
Heavy Atom Count: 19  
Hydrogen Bond Acceptor Count: 3  
Hydrogen Bond Donor Count: 0  
Isotope Atom Count: 0  
Rotatable Bond Count: 4  
Undefined Atom Stereocenter Count: 0  
Undefined Bond Stereocenter Count: 0  
XLogP3: 2.6  
Literature fold

Title: Synthesis and evaluation of a set of 4-phenylpiperidines and 4-phenylpiperazines as D2 receptor ligands and the discovery of the dopaminergic stabilizer 4-[3-(methylsulfonyl)phenyl]-1-propylpiperidine (huntexil, pridopidine, ACR16).

Journal: Journal of medicinal chemistry20100325

Title: Coadministration of (-)-OSU6162 with l-DOPA normalizes preproenkephalin mRNA expression in the sensorimotor striatum of primates with unilateral 6-OHDA lesions.

Journal: Experimental neurology20010501

Title: Effects of acute and repeated treatment with a novel dopamine D2 receptor ligand on L-DOPA-induced dyskinesias in MPTP monkeys.

Journal: European journal of pharmacology20010202

Title: (-)-OSU 6162 inhibits levodopa-induced dyskinesias in a monkey model of Parkinson's disease.

Journal: Neuroreport19970728

Building Blocks More >
147127-19-3
147127-19-3
(S)-(((1-(6-Amino-9h-purin-9-yl)propan-2-yl)oxy)methyl)phosphonic acid
AA001EJR | MFCD21604708
1475-11-2
1475-11-2
1-(3,4-Dichlorophenyl)ethanol
AA001EVD | MFCD00021865
14779-25-0
14779-25-0
(2E)-3-(5-Methyl-2-furyl)acrylic acid
AA001F4Q | MFCD00186942
14816-20-7
14816-20-7
Phosphorothioic acid, O-[[(2-chlorophenyl)cyanomethylene]azanyl] O,O-diethyl ester
AA001FES | MFCD00078643
141018-30-6
141018-30-6
β-D-Ribofuranuronamide, 1-[6-amino-2-(1-hexyn-1-yl)-9H-purin-9-yl]-1-deoxy-N-ethyl-
AA001FO6 | MFCD03095611
1414943-88-6
1414943-88-6
1,3,5-Triazin-2-amine, 4-(4-fluoro-2-methoxyphenyl)-N-[3-[(S-methylsulfonimidoyl)methyl]phenyl]-
AA001GEO | MFCD30502894
1416440-62-4
1416440-62-4
3-Bromo-5-chloroquinoline
AA001GQ9 | MFCD22690572
141872-92-6
141872-92-6
4-Fluoro-1-methyl-2-(trifluoromethyl)benzene
AA001H88 | MFCD11226544
14208-52-7
14208-52-7
3-Phenylisothiazol-5-amine
AA001HNF | MFCD07382685
1423032-42-1
1423032-42-1
Cyclopropaneethanamine, N-methyl-, hydrochloride (1:1)
AA001I23 | MFCD22421906
Submit
© 2017 AA BLOCKS, INC. All rights reserved.